Advertisement

TRPV1 agonist therapies in bladder diseases

  • Francisco Cruz
  • Carlos Silva
  • Paulo Dinis
Part of the Progress in Inflammation Research book series (PIR)

Keywords

Nerve Growth Factor International Prostate Score Symptom Vanilloid Receptor Autonomic Dysreflexia Neurogenic Detrusor Overactivity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    de Groat WC (1997) A neurologic basis for the overactive bladder. Urology 50(Suppl 6A): 36–52PubMedGoogle Scholar
  2. 2.
    Yokoyama O, Nagano K, Kawaguchi K, Ueki O, Mitsuo O (1994) The influence of prostatic urethral anesthesia in overactive detrusor in patients with benign prostatic hyperplasia. J Urol 151: 1554–1556PubMedGoogle Scholar
  3. 3.
    Chai TC, Gray ML, Steers W (1998) The incidence of a positive ice water test in bladder outlet obstructed patients: evidence for bladder neural plasticity. J Urol 160: 34–38PubMedGoogle Scholar
  4. 4.
    Smet PJ, Moore KH, Jonavicius J (1997) Distribution and colocalization of calcitonin gene-related peptide tachykinins and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab Invest 77: 37–49PubMedGoogle Scholar
  5. 5.
    Steers WD, de Groat WC (1988) Effect of bladder outlet obstruction on micturition reflex pathways in the rat. J Urol 140: 864–871PubMedGoogle Scholar
  6. 6.
    Cruz F, Avelino A, Coimbra A (1996) Desensitization follows excitation of bladder primary afferents by intravesical capsaicin, as shown by c-fos activation in the rat spinal cord. Pain 64: 553–557PubMedCrossRefGoogle Scholar
  7. 7.
    Avelino A, Cruz F, Coimbra A (1999) Intravesical resiniferatoxin desensitizes rat bladder sensory fibres without causing intense noxious excitation. A c-fos study. Eur J Pharmacol 378: 17–22PubMedCrossRefGoogle Scholar
  8. 8.
    Avelino A, Cruz F (2000) Peptide immunoreactivity and ultrastructure of rat urinary bladder nerve fibers after topical desensitization by capsaicin or resiniferatoxin. Auton Neurosci 86: 37–46PubMedGoogle Scholar
  9. 9.
    Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55(Suppl 5A): 33–46PubMedGoogle Scholar
  10. 10.
    Fowler CJ, Jewkes D, McDonald WI, Lynn B, de Groat WC (1992) Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 339: 1239PubMedGoogle Scholar
  11. 11.
    Fowler CJ, Beck RO, Gerrard S, Betts CD, Fowler CG (1994) Intravesical capsaicin for the treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 57: 169–173PubMedGoogle Scholar
  12. 12.
    Geirsson G, Fall M, Sullivan L (1995) Clinical and urodynamic effects of intravesical capsaicin treatment in patients with chronic traumatic spinal detrusor hyperreflexia. J Urol 154: 1825–1829PubMedGoogle Scholar
  13. 13.
    Das A, Chancellor MB, Watanabe T, Sedor J, Rivas DA (1996) Intravesical capsaicin in neurogenic impaired patients with detrusor hyperreflexia. J Spinal Cord Med 19: 190–193PubMedGoogle Scholar
  14. 14.
    Igawa Y, Komiyama I, Nishizawa O, Ogawa A (1996) Intravesical capsaicin inhibits autonomic dysreflexia in patients with spinal cord injury. Neurourol Urodyn 15: 374–375Google Scholar
  15. 15.
    Cruz F, Guimarães M, Silva C, Rio ME, Coimbra A, Reis M (1997) Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. J Urol 157: 585–589PubMedGoogle Scholar
  16. 16.
    De Ridder D, Chandiramani V, Dasgupta P, Van Poppel H, Baert L, Fowler CJ (1997) Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup. J Urol 158: 2087–2092PubMedGoogle Scholar
  17. 17.
    de Séze M, Wiart L, Joseph PA, Dosque JP, Mazaux JM, Barat M (1998) Capsaicin and neurogenic detrusor hyperreflexia. A double blind placebo controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 17: 513–523PubMedGoogle Scholar
  18. 18.
    Cruz F, Guimarães M, Silva C, Reis M (1997) Supression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 350: 640–641PubMedCrossRefGoogle Scholar
  19. 19.
    Lazzeri M, Beneforti P, Turini D (1997) Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. J Urol 158: 2093–2096PubMedGoogle Scholar
  20. 20.
    Lazzeri M, Spinelli M, Beneforti P, Zanollo A, Turini D (1998) Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases. Scand J Urol Nephrol 32: 331–334PubMedGoogle Scholar
  21. 21.
    Silva C, Rio ME, Cruz F (2000) Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia. Eur Urol 38: 444–452PubMedCrossRefGoogle Scholar
  22. 22.
    Brady CM, Apostolidis AN, Harper M, Yiangou Y, Beckett A, Jacques TS, Freeman A, Scaravilli F, Fowler CJ, Anand P (2004) Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 93: 770–776PubMedCrossRefGoogle Scholar
  23. 23.
    Cruz F, Silva C, Ribeiro M, Avelino A (2002) The effect of intravesical resiniferatoxin in neurogenic forms of bladder overactivity. Preliminary results of a randomised placebo controlled clinical trial. Neurourol Urodyn 21: 426–427Google Scholar
  24. 24.
    Park WH, Kim HG, Park BJ, Kim DY, Oh DJ, Lim YS, Shim HB (1999) Comparison of the effects of intravesical capsaicin and resiniferatoxin for treatment of detrusor hyperreflexia in patients with spinal cord injury. Neurourol Urodyn 18: 402Google Scholar
  25. 25.
    Giannantoni A, Di Stasi SM, Stephen RL, Navarra P, Scivoletto G, Mearini E, Porena M (2002) Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 167: 1710–1714PubMedGoogle Scholar
  26. 26.
    de Seze M, Wiart L, de Seze MP, Soyeur L, Dosque JP, Blajezewski S, Moore N, Brochet B, Mazaux JM, Barat M, Joseph PA (2004) Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a doubleblind, randomized, controlled study. J Urol 171: 251–255PubMedGoogle Scholar
  27. 27.
    Peters TJ, Donovan JL, Kay HE, Abrams P, de la Rosette JJMCH, Porru D, Thuroff JW (1997) The International Continence Society “Benign Prostatic Hyperplasia” study: the bothersomeness of urinary symptoms. J Urol 157: 885–889PubMedGoogle Scholar
  28. 28.
    Dinis P, Silva J, Ribeiro MJ, Avelino A, Reis M, Cruz F (2004) Bladder C-fiber desensitization induces a long-lasting improvement of BPH-associated storage LUTS. A pilot study. Eur Urol 46: 88–93; discussion 93-94PubMedCrossRefGoogle Scholar
  29. 29.
    Kuo H (2003) Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions. J Urol 170: 835–839PubMedGoogle Scholar
  30. 30.
    Debruyne FJM, Heesakkers JPFA, (2004) Clinical and socioeconomic relevance of overactive bladder. Urology 63(3A): 42–44PubMedGoogle Scholar
  31. 31.
    Silva C, Ribeiro MJ, Cruz F (2002) The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 168: 575–579PubMedGoogle Scholar
  32. 32.
    Palma P, Dambros M, Thiel M, Fraga R, Riccetto CLZ, Netto NR (2003) Resultados preliminares da resiniferatoxina no tratamento de pacientes com instabilidade detrusora. Urodinamica Aplicada 16: 261–267Google Scholar
  33. 33.
    Szallasi A, Blumberg PM (1999) Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 51: 159–211PubMedGoogle Scholar
  34. 34.
    Avelino A, Cruz C, Nagy I, Cruz F, (2002) Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience 109: 787–798PubMedCrossRefGoogle Scholar
  35. 35.
    Brady C, Apostolidis AN, Yiangou Y, Baecker PA, Ford AP, Fowler CJ, Anand P (2003) P2X3-immunoreactive nerve fibers in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin (RTX). Eur Urol 2(Suppl): 93 (abstract)Google Scholar
  36. 36.
    Avelino A, Cruz C, Cruz F (2002) Nerve growth factor regulates galanin and c-jun overexpression occurring in dorsal root ganglion cells after intravesical resiniferatoxin application. Brain Res 951: 264–269PubMedCrossRefGoogle Scholar
  37. 37.
    Miller MS, Buck SH, Sipes IG, Yamamura HI, Burks TF (1982) Regulation of substance P by nerve growth factor: disruption by capsaicin. Brain Res 250: 193–196PubMedCrossRefGoogle Scholar
  38. 38.
    Taylor DCM, Pierau FK, Szolcsányi J (1984) Long lasting inhibition of horseradish peroxidase (HRP) transport in sensory nerves induced by capsaicin treatment of the receptive field. Brain Res 298: 45–49PubMedCrossRefGoogle Scholar
  39. 39.
    Vizzard MA (2000) Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol 161: 273–284PubMedCrossRefGoogle Scholar
  40. 40.
    Seki S, Sasaki K, Fraser MO, Igawa Y, Nishizawa O, Chancellor MB, de Groat WC, Yoshimura N (2002) Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol 168: 2269–2274PubMedGoogle Scholar
  41. 41.
    Steers WD, Kolbeck S, Creedon D, Tuttle JB (1991) Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 88: 1709–1715PubMedCrossRefGoogle Scholar
  42. 42.
    Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, Yoshimura N (2001) The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol 165: 975–979PubMedGoogle Scholar
  43. 43.
    Steers WD, Creedon DJ, Tuttle JB (1996) Immunity to nerve growth factor prevents afferent plasticity following urinary bladder hypertrophy. J Urol 155: 379–385PubMedGoogle Scholar
  44. 44.
    Dasgupta P, Chandiramani V, Parkinson MC, Beckett A, Fowler CJ (1998) Treating the human bladder with capsaicin: is it safe? Eur Urol 33: 28–31PubMedCrossRefGoogle Scholar
  45. 45.
    Silva C, Avelino A, Souto-Moura C, Cruz F (2001) A light and electron microscope histopathological study of the human bladder mucosa after intravesical resiniferatoxin application. BJU Int 88: 355–360PubMedCrossRefGoogle Scholar
  46. 46.
    Dinis P, Charrua A, Avelino A, Cruz F (2004) Intravesical resiniferatoxin decreases spinal c-fos expression and increases bladder volume to reflex micturition in rats with chronic inflamed urinary bladders. BJU Int 94: 153–157PubMedCrossRefGoogle Scholar
  47. 47.
    Maggi CA, Barbanti G, Santicioli P, Beneforti P, Misuri D, Meli A, Turini D (1989) Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans. J Urol 142: 150–154PubMedGoogle Scholar
  48. 48.
    Barbanti G, Maggi CA, Beneforti P, Baroldi P, Turini D (1993) Relief of pain following intravesical capsaicin in patients with hypersensitive disorders of the lower urinary tract. BJU 71: 686–691PubMedCrossRefGoogle Scholar
  49. 49.
    Lazzeri M, Beneforti P, Benaim G, Maggi CA, Lecci A, Turini D (1996) Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. J Urol 156: 947–952PubMedGoogle Scholar
  50. 50.
    Lazzeri M, Beneforti P, Spinelli M, Zanollo A, Barbagli G, Turini D (2000) Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J Urol 164: 676–679PubMedGoogle Scholar
  51. 51.
    Lazzeri M, Spinelli M, Beneforti P, Malaguti S, Giardiello G, Turini D (2004) Intravesical infusion of resiniferatoxin by a temporary in situ drug delivery system to treat interstitial cystitis: a pilot study. Eur Urol 45: 98–102PubMedCrossRefGoogle Scholar
  52. 52.
    Guo A, Vulchanova L, Wang J, Li X, Elde R (1999) Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoreceptor and IB4 binding sites. Eur J Neurosci 11: 946–958PubMedCrossRefGoogle Scholar
  53. 53.
    Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, Malmberg AB, Cain G, Berson A, Kassotakis L et al (2000) Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407: 1011–1015PubMedCrossRefGoogle Scholar
  54. 54.
    Birder LA, Nakamura Y, Kiss S, Nealen ML, Barrick S, Kanai AJ, Wang E, Ruiz G, De Groat WC, Apodaca G et al (2002) Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 5: 856–860PubMedCrossRefGoogle Scholar
  55. 55.
    Avelino A, Dinis P, Charrua A., Nagy I, Yacoob M, Cruz F (2003) The endogenous TRPV1 ligand anandamide increases in the rat inflamed urinary bladder and may contribute to inflammatory pain. Program 608.3. Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington DCGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2005

Authors and Affiliations

  • Francisco Cruz
    • 1
  • Carlos Silva
    • 1
  • Paulo Dinis
    • 1
  1. 1.Department or UrologyHospital S. João and Faculty of Medicine of PortoPortoPortugal

Personalised recommendations